"Diflorasone diacetate"

application on the mothers’ skin, appreciable levels of betamethasone 17, 21-dipropionate were detected in the fetal blood of mice and rabbits.20 Animal studies have found topical corticosteroids are also teratogenic. Diflorasone diacetate cream caused cleft palate after applied to pregnant rats’ skin at a dose of 0.001 mg/kg/day, which was just one-third of the equivalent human topical dose. The treated rats had a higher rate of fetal death than untreated controls when the dose was increased to 0.5 mg/kg/day.21 After topical application of diflorasone diacetate 0.016 mg/kg/day to pregnant rabbits, depressed fetal growth, external anomalies (31.9%), cleft palate (22.2%), and visceral defects (45.5%) were found.22 To sum up, animal experiments demonstrated that topical application of topical

, Hydrocortisone Cream, Hydrocortisone Topical, Halobetasol Propionate, Ultravate, Temovate, Diprolene, Diflorasone diacetate, Psorcon, Amcinonide, Cyclocort, Diprosone, Mometasone furoate, Elocon, Florone, Fluocinonide, Lidex, Maxiflor, Desoximetasone, Topicort, Halcinonide, Halog, Hydrocortisone valerate, Westcort, Kenalog, Flurandrenolide, Cordran, Betamethasone valerate, Valisone, Hydrocortisone butyrate , spray cream 3. Diflorasone diacetate (Psorcon) 0.05% ointment 4. Flucinonide (Lidex) 0.1% cream 5. Flurandrenolide 4 mcg/cm2 tape 6. Halobetasol Propionate (Ultravate) 0.05% cream and ointment VI. Preparations: Level 2 (Very High Potency) 1. Halcinonide (Halog) 0.1% cream 2. Amcinonide (Cyclocort) 0.1% ointment 3. Betamethasone Dipropionate augmented (Diprolene AF) 0.05% cream 4. Betamethasone

, groups A [eg, hydrocortisone, hydrocortisone-21-butyrate] and D2 [eg, hydrocortisone-17-butyrate] may be much more frequently observed than allergy to those corticosteroid molecules that are halogenated and have a methyl group at C16 (ie, groups D1 [eg, betamethasone dipropionate, clobetasol propionate, diflorasone diacetate, fluticasone propionate, mometasone furoate] and C [eg, desoximetasone

, groups A [eg, hydrocortisone, hydrocortisone-21-butyrate] and D2 [eg, hydrocortisone-17-butyrate] may be much more frequently observed than allergy to those corticosteroid molecules that are halogenated and have a methyl group at C16 (ie, groups D1 [eg, betamethasone dipropionate, clobetasol propionate, diflorasone diacetate, fluticasone propionate, mometasone furoate] and C [eg, desoximetasone

[eg, hydrocortisone-17-butyrate] may be much more frequently observed than allergy to those corticosteroid molecules that are halogenated and have a methyl group at C16 (ie, groups D1 [eg, betamethasone dipropionate, clobetasol propionate, diflorasone diacetate, fluticasone propionate, mometasone furoate] and C [eg, desoximetasone, desoxymethasone]). [30] C16-methylated corticosteroids should

, groups A [eg, hydrocortisone, hydrocortisone-21-butyrate] and D2 [eg, hydrocortisone-17-butyrate] may be much more frequently observed than allergy to those corticosteroid molecules that are halogenated and have a methyl group at C16 (ie, groups D1 [eg, betamethasone dipropionate, clobetasol propionate, diflorasone diacetate, fluticasone propionate, mometasone furoate] and C [eg, desoximetasone

without C16-methyl substitution in the D-ring (ie, groups A [eg, hydrocortisone, hydrocortisone-21-butyrate] and D2 [eg, hydrocortisone-17-butyrate] may be much more frequently observed than allergy to those corticosteroid molecules that are halogenated and have a methyl group at C16 (ie, groups D1 [eg, betamethasone dipropionate, clobetasol propionate, diflorasone diacetate, fluticasone propionate

[eg, hydrocortisone-17-butyrate] may be much more frequently observed than allergy to those corticosteroid molecules that are halogenated and have a methyl group at C16 (ie, groups D1 [eg, betamethasone dipropionate, clobetasol propionate, diflorasone diacetate, fluticasone propionate, mometasone furoate] and C [eg, desoximetasone, desoxymethasone]). [30] C16-methylated corticosteroids should

, Hydrocortisone Cream, Hydrocortisone Topical, Halobetasol Propionate, Ultravate, Temovate, Diprolene, Diflorasone diacetate, Psorcon, Amcinonide, Cyclocort, Diprosone, Mometasone furoate, Elocon, Florone, Fluocinonide, Lidex, Maxiflor, Desoximetasone, Topicort, Halcinonide, Halog, Hydrocortisone valerate, Westcort, Kenalog, Flurandrenolide, Cordran, Betamethasone valerate, Valisone, Hydrocortisone butyrate , spray cream 3. Diflorasone diacetate (Psorcon) 0.05% ointment 4. Flucinonide (Lidex) 0.1% cream 5. Flurandrenolide 4 mcg/cm2 tape 6. Halobetasol Propionate (Ultravate) 0.05% cream and ointment VI. Preparations: Level 2 (Very High Potency) 1. Halcinonide (Halog) 0.1% cream 2. Amcinonide (Cyclocort) 0.1% ointment 3. Betamethasone Dipropionate augmented (Diprolene AF) 0.05% cream 4. Betamethasone

. However, systemically administered ASA significantly reduced the DC migration to the draining lymph node. In contrast, topically administered indomethacin reduced the inflammatory response, but had only minor effects on DC migration, whereas diflorasone diacetate reduced both inflammatory reaction and DC migration. Thus, NSAIDs may differ in their inhibitory action in immunological inflammation.

TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines. Skin-infiltrating T cells play a predominant role in allergic and inflammatory skin diseases such as atopic dermatitis and allergic contact dermatitis. These T cells are attracted by chemotactic factors, e.g. RANTES (regulation concentrations were determined by enzyme-linked immunosorbent assay. The effects on chemokine concentrations of the highly selective phosphodiesterase 4 inhibitor cilomilast and the glucocorticoid diflorasone diacetate were studied in mouse ears. RANTES and TARC were elevated in both models of allergic contact dermatitis 24 h after challenge, whereas CTACK remained unchanged. The increase in RANTES

Diflorasone diacetate: vasoconstrictor activity and clinical efficacy of a new topical corticosteroid. Diflorasone diacetate, a new topical corticosteroid, was generally more potent than three high potency reference standards (fluocinonide, beta-methasone 17-valerate and fluocinolone acetonide) when the compounds were dissolved in 95% alcohol and applied in vasoconstrictor assays in healthy volunteers. On the basis of additional vasoconstrictor assay results, a 0-05% concentration of the steroid in a cream vehicle containing 15% propylene glycol was developed for therapeutic evaluation. In a double-blind comparison in 384 patients with dermatoses, 0-05% diflorasone diacetate cream was as effective as 0-05% fluocinonide cream in the therapy of lesions of psoriasis or atopic/neurodermatitis.

Once-daily treatment of psoriasis with topical glucocorticosteroid ointments. A double-blind, vehicle-controlled comparison of two glucocorticosteroid ointments demonstrated that once-daily therapy for psoriasis was effective. After 3 weeks of once-daily therapy, psoriasis subjects treated with betamethasone dipropionate (BD) ointment or diflorasone diacetate (DD) ointment showed statistically

[Therapy of eczema. Once daily use of diflorasone diacetate in comparison to thrice daily use of betamethasone-17-valerate].

Once daily application of diflorasone diacetate ointment compared with betamethasone valerate ointment twice daily in patients with eczematous dermatoses. The clinical efficacy of 0.05% diflorasone diacetate applied once daily, for eczematous dermatoses, was compared with the twice daily application of betamethasone valerate. Both agents were supplied as ointments. Sixty patients were randomized

Comparative efficacy of once a day diflorasone diacetate and twice a day betamethasone valerate ointment applications in eczematous dermatitis. The efficacy of once a day applications of 0.05% diflorasone diacetate ointment and twice a day applications of 0.1% betamethasone valerate ointment was compared in 70 patients with eczematous dermatitis. Altogether 32 patients completed the 3-week study . Fourteen patients in the diflorasone group and 6 on betamethasone left the study earlier because of total (100%) improvement of lesions. Eight patients left because of unsatisfactory progress and 6 because of personal reasons. There were only two noticeable differences observed between treatment groups. At Week 2, the diflorasone diacetate group improved significantly more than the betamethasone valerate

Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects. In this 14-day, double-blind, in-clinic study, 24 healthy male volunteers were assigned at random to one of four treatment groups to compare the effects of a new formulation of 0.05% diflorasone diacetate ointment in a vehicle of propylene glycol (PG) with the effects of ointments of 0.05% fluocinonide , 0.05% clobetasol propionate, or the vehicle for diflorasone diacetate PG. The medication was applied to 75% of each subject's total body surface once a day for six consecutive days. During treatment and four days before and four days after treatment, various indicators of adrenal suppression were measured. A reduction in plasma cortisol levels was seen in several patients in each treatment group

Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. We report the results of a 2-week double-blind, parallel clinical trial comparing two superpotent topical glucocorticosteroid ointments, diflorasone diacetate 0.05% and betamethasone dipropionate 0.05%, in psoriatic adults. Both corticosteroid ointments were fast acting

Clobetasol propionate ointment 0.05% versus diflorasone diacetate ointment 0.05% in moderate to severe psoriasis.

[Comparative study of diflorasone diacetate and clobetasol-17-propionate in PUVA-resistant psoriasis]. In a double-blind controlled trial, we have compared the therapeutic effectiveness of Diflorason-Diacetate and Clobetasol-17-propionate with 50 PUVA-resistent psoriatics. Both externals resulted in a highly significant decline of psoriatic symptoms. The difference in therapeutic achievement between the two respective groups was statistically not significant. According to the physician's overall judgement, however, Clobetasol was favored significantly over Diflorasone-Diacetate, while the patients only showed a slight preference for Clobetasol. Based on these findings and previously published results, Diflorasone-Diacetate may be classified as one of the most effective skin corticosteroids